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Abstract
Background: We examined the influence of overweight and obesity on pulmonary function, exercise tolerance,
quality of life and response to pulmonary rehabilitation in COPD.
Methods: 261 patients with COPD were divided into three groups: normal body mass index (BMI), overweight and
obese. Baseline and post rehabilitation pulmonary function, 6-min walking test (6MWT), endurance time during a
constant workrate exercise test (CET) and St. George’s Respiratory Questionnaire (SGRQ) scores were compared
between all three classes of BMI.
Results: At baseline, obese and overweight patients had less severe airflow obstruction compared to normal BMI
patients. There was no baseline difference in CET performance or SGRQ scores across BMI classes and 6MWT was
reduced in the presence of obesity (p < 0.01). Compared to baseline, post-rehabilitation 6MWT, CET performance
and SGRQ scores improved significantly in each group (p < 0.01), but 6MWT was still significantly lower in the
presence of obesity.
Conclusions: Walking, but not cycling performance was worse in obese patients. This difference was maintained
post rehabilitation despite significant improvements. Weight excess may counterbalance the effect of a better
preserved respiratory function in the performance of daily activities such as walking. However, obesity and
overweight did not influence the magnitude of improvement after pulmonary rehabilitation.
Background
Chronic obstructive pulmonary disease (COPD) is asso-
ciated with dyspnea and exercise intolerance, two major
impediments to quality of life. Although low body
weight [1] and muscle wasting [2] have traditionally
been the focus of nutritional management in COPD,
recent data indicate that obesity is becoming frequent in
this disease [3]. On one hand, a high body mass index
(BMI) appears to convey a survival advantage to patients
with COPD[1,4]. On the other hand, obesity by itself
may compromise lung function[5], decrease exercise tol-
erance particularly during weight bearing activities [6,7],
and quality of life[8], leading to greater disability[9,10].
The effects of obesity in combination with COPD on
exercise tolerance and dyspnea have received little
attention. In one study, obese patients with COPD had
a greater peak exercise capacity and reduced dyspnea
perception at a standardized ventilation during incre-
mental cycling exercise compared to their lean counter-
parts [11]. These counterintuitive beneficial effects of
obesity were felt to be related to reduced operating lung
volumes during exercise in the obese individuals. Other
studies showed that the 6-min walking distance [3], but
not constant exercise cycling test time [12], was reduced
in obese patients with COPD compared to non-obese
patients highlighting the importance of taking into
account the exercise testing modality before concluding
about the impact of obesity on exercise capacity in
COPD. Whether overweight may also influence exercise
capacity in COPD has not yet been addressed.
Pulmonary rehabilitation addresses the systemic con-
sequences of COPD, beyond the impairment in lung
function. As summarized in a recent meta-analysis[13]
pulmonary rehabilitation improves dyspnea, exercise
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tolerance and quality of life. Because of the growing pre-
valence of weight excess in COPD[14], it is important to
learn about the impact of overweight and obesity on
pulmonary rehabilitation. A retrospective study [3]
showed that obesity did not adversely affect rehabilita-
tion outcomes, although data obtained prospectively
would be useful to confirm these findings.
Based on the existing data suggesting that overweight
and obesity may interact with COPD, our hypothesis
was that increasing BMI in COPD would reduce exer-
cise tolerance, increase exertional dyspnea and reduce
functional status during walking but not cycling and
compromise the response to pulmonary rehabilitation in
patients with COPD. This study was thus undertaken to
investigate the effects of overweight and obesity com-
bined with COPD on 1) resting pulmonary function; 2)
6-min walking distance and endurance time during a
constant workrate cycling exercise test (CET time) 3)
health-related quality of life and 4) improvement of
these parameters following pulmonary rehabilitation. To
address these issues, we took advantage of a prospective




Patients with COPD about to take part in pulmonary
rehabilitation were recruited in 10 study centers across
Canada. Inclusion criteria were: stable COPD, post-
bronchodilator forced expiratory volume in one second
(FEV1) <70% predicted and FEV1/forced vital capacity
(FVC) <70%. Exclusion criteria were: participation to
pulmonary rehabilitation in the preceding 12 months,
living in a long term care facility and a diagnosis of
asthma, congestive heart failure or dementia. All
patients gave informed consent to participate in the
study. Ethics committee from all 10 study sites approved
this research project.
Study design
The data for this study was collected as a part of a pro-
spective observational study of pulmonary rehabilitation
in Canada. The main objective of this cohort was to com-
pare home versus hospital-based pulmonary rehabilita-
tion [15]. The secondary objectives were to identify
possible predictors of the response to pulmonary rehabi-
litation, including obesity, and to evaluate the responsive-
ness of different evaluative tools to assess the effects of
pulmonary rehabilitation[16]. The participating centres
agreed on a pre-established research protocol describing
the evaluation process that was standardized and per-
formed by qualified study personels. Study monitoring
was ensured by one of the author (SB). The length of the
pulmonary rehabilitation programs (6 to 12 weeks) could
not be standardized because of different rehabilitation
capacity between centres. Patients’ assessment included a
medical history, pulmonary function tests, and CET,
6MWT and health status measured by the St. George’s
Respiratory Questionnaire (SGRQ). Dyspnea at rest was
evaluated with the MRC dyspnea score [17]. Data was col-
lected at baseline and immediately after the pulmonary
rehabilitation program. Patients were classified according
to BMI classification of the World Health Organization
[18] into normal BMI (BMI 18.5 - 24.99 kg·m-2), over-
weight (25 - 29.99 kg·m-2) and obese (>30 kg·m-2).
Pulmonary function
Spirometry and lung volumes were measured according
to recommended procedures [19]. Results were com-
pared with predicted normal values from the European
Respiratory Society [20]. Disease severity was categorized
according to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) classification system [21].
Constant workrate cycling exercise test (CET)
CET was performed on a cycle ergometer with a work-
load set at 80% of peak work capacity achieved during
incremental cycle ergometry. Patients were asked to
cycle for as long as possible [22]. The minimum clini-
cally important difference (MCID) in exercise time was
set at 100 s [16].
Six-minute walking test (6MWT)
The 6MWT was administered in an enclosed corridor in
accordance to the procedures recommended by the
American Thoracic Society (ATS) [23]. The MCID in
walking distance was set at 54 m [24]. We also calcu-
lated the body weight-walking distance product in m·kg
(walk-work) at baseline[25].
Health status
Health status was evaluated using French or English ver-
sions of the SGRQ[26]. This disease-specific question-
naire has been extensively validated in patients with all
grades of respiratory disease including advanced COPD
[27]. A score change of 4 points was considered clini-
cally significant [28].
Symptoms assessment
Ratings of perceived exertion were reported by patients
at the end of exercise tests (CET and 6MWT) on a 10-
point Borg scale, for dyspnea and leg fatigue. The MCID
for Borg scores was set at 1 unit [29].
Pulmonary rehabilitation
Rehabilitation program consisted of 6 to 12 weeks of tri-
weekly 90-minute exercise sessions that integrated sta-
tionary bicycle endurance training, resistance exercises,
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and patient education, which has been described exten-
sively elsewhere[15,30]. The exercise training program
was directly supervised (n = 190) or was delivered at
home (n = 71). Since these two interventions gave simi-
lar results on dyspnea, quality of life and exercise toler-
ance[15], data from these two training strategies were
combined in the present study.
Statistical analysis
Results are reported as mean ± SD. A p value <0.05
was considered as statistically significant. One-way
ANOVA was used to compare baseline characteristics,
except gender for which we used the Pearson’s chi-
square. Post rehabilitation data was compared to base-
line using repeated measures two-way ANCOVAs
(group, intervention) using baseline spirometric data
and lung volumes as covariates (FEV1% predicted,
FEV1/FVC ratio, functional residual capacity (FRC)%
predicted, residual volume (RV)% predicted, total lung
capacity (TLC), inspiratory capacity (IC)/TLC ratio).
The normality assumption was verified using the
Shapiro-Wilk’s statistic while the homogeneity of var-
iances was verified graphically with the residuals plot.
Univariate and multivariate regression analyses were
carried out to identify possible correlates of the
response to pulmonary rehabilitation using age, sex,
BMI, length of rehabilitation program and all the pul-
monary function tests reported in table 1 as indepen-
dent variables. All the analyses were done using SAS
software, release 9.2 (SAS Institute inc., NC).
Results
Baseline characteristics
Three hundred patients were initially enrolled in the
present study. A 13% drop-out rate was observed during
pulmonary rehabilitation. The drop-outs were evenly
distributed among the three groups. Reasons for
dropping-out were: patient withdrawal (11%), lost to fol-
low-up (1.5%) and death (0.5%). We report here data for
the 261 patients who have completed pulmonary rehabi-
litation and whose baseline characteristics are presented
in table 1. Patients had a mean FEV1 of 46 ± 15% of
predicted value. GOLD stage distribution was as follows:
stage 1, 1% of the total population; stage 2, 40%; stage 3,
44%; and stage 4, 15% (figure 1). Mean age was 65 ± 8
years and 57% of patients were males. There were no
patients with BMI under 18.5 kg/m2 and only 5 patients
with BMI >40 kg/m2.
Sixty percent of the study population was either obese
or overweight, a proportion reflective of the Canadian
population aged 40 years or older[31]. FEV1 (L and %),
FEV1/FVC ratio and inspiratory capacity (IC) to TLC
ratio (IC/TLC) were significantly lower in the normal
BMI group than the other two groups (p < 0.05).
Residual volume (RV, L and %), total lung capacity
(TLC, L and %), and BODE scores[4] were significantly
higher in the normal BMI group than in the other two
groups (p < 0.05). Functional residual capacity (FRC,
L and %) was significantly higher in the normal BMI
group than in the obese group. There was a larger pro-
portion of GOLD stage II patients in the overweight and
obese groups (figure 1).
At baseline, 6MWT distance in the obese group was
65 m shorter compared to normal BMI (p < 0.01) and
49 m shorter compared to overweight (p < 0.01) (table 1
and figure 2). Work-walk at baseline was significantly
higher in the obese group (32779 ± 11078 m·kg, p <
0.01) compared to the other two groups and was higher
in the overweight group (29590 ± 8045 m·kg) compared
to normal BMI (23296 ± 5902 m·kg, p < 0.01). At base-
line, CET time was similar across all BMI categories
(p = 0.8) (table 1 and figure 2).
Borg dyspnea and leg fatigue scores after 6MWT were
higher in the obese group at baseline (p < 0.05) (Figure
3a and 3b). During CET, Borg dyspnea and leg fatigue
scores were similar between groups. Baseline SGRQ
total scores were not significantly different between
groups (table 1).
Effects of pulmonary rehabilitation according to BMI
The duration and modality (home versus hospital-based)
of pulmonary rehabilitation programmes were similar
across the three BMI categories (table 1). Albeit small,
the pre versus post rehabilitation difference in the
6-min walking distance were statistically significant (p <
0.01) and of similar magnitude within each group (mean
15-21 m, p = 0.92) (figure 2). Improvement in CET time
following rehabilitation was also similar in the 3 groups
and reached the clinical and statistical thresholds within
each group (mean 175-216 seconds, p < 0.01) (figure 2).
There was no significant reduction in 6MWT Borg
scores with rehabilitation within the 3 BMI categories
(figure 3a and 3b). This is in contrast to CET Borg
scores and SGRQ scores which were significantly
reduced (1.0-1.3 points, p < 0.01 and 7-8 points, p <
0.01 respectively) after rehabilitation in all three BMI
groups (figure 3, panel c and d, and figure 4). In univari-
ate and multivariate regression analyses, the changes in
6MWT distance, CET time and SGRQ scores as depen-
dant variables were not statistically associated with BMI
nor with any of the potential correlates of the response
to rehabilitation that are outlined in the statistical analy-
sis section.
MCID for the 6MWT, CET and SGRQ was reached
by 19%, 46%, and 60% respectively in the entire study
population. Table 2 shows the proportional MCID
attainment according to BMI category. This proportion
for the 6MWT was smaller for obese than normal BMI
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(15% vs 24%, p < 0.01) but was similar across groups for
CET, SGRQ and Borg scores.
The changes in BMI after rehabilitation were small
and not statistically significant averaging -0.03 ± 0.98
kg/m2 (range: -6.26 to 3.94 kg/m2). There was a signifi-
cant reduction in BODE scores in the 3 groups with
rehabilitation with a post-rehabilitation BODE scores of
3.1 ± 1.8, 2.5 ± 1.6, 2.6 ± 1.6, for normal BMI, overweight
and obese, respectively, p < 0.01 versus pre-rehabilitation.
Discussion
This study reports on the impact of obesity and over-
weight in a large prospective cohort of patients with
COPD participating in pulmonary rehabilitation. The
Table 1 Baseline characteristics of patients
Normal BMI Overweight Obese ANOVA
n = 88 n = 95 n = 78 p-value
Age, years 66.0 ± 9.4 65.7 ± 8.2 65.4 ± 8.0 NS
Sex, % of men 56 61 59 NS
Body mass index, kg/m2 22.3 ± 1.8* 27.5 ± 1.5* 35.1 ± 3.5 <0.001
Height (cm) 164 ± 9.1 165 ± 9.2 163 ± 9.8 NS
Weight (kg) 61 ± 8.6* 75 ± 9.8* 91 ± 14.6 <0.001
BODE score 3.9 ± 2.0* 3.1 ± 2.0 3.2 ± 2.4 0.002
Pulmonary function
FEV1, L 1.02 ± 0.39* 1.18 ± 0.42 1.14 ± 0.38 0.002
% predicted 42 ± 15* 49 ± 15 49 ± 17 0.002
FVC, L 2.7 ± 0.8 2.6 ± 0.8 2.5 ± 0.9 NS
% predicted 86 ± 22 83 ± 21 82 ± 23 NS
FEV1/FVC, % 40 ± 10* 45 ± 12* 49 ± 12 0.001
FRC, L 5.0 ± 1.6† 4.4 ± 1.5 4.1 ± 1.7 <0.001
% predicted 159 ± 42† 142 ± 41 135 ± 45 <0.001
RV, L 4.2 ± 1.4* 3.6 ± 1.4 3.5 ± 1.5 0.002
% predicted 178 ± 60* 157 ± 58 151 ± 64 0.006
TLC, L 6.8 ± 1.7* 6.3 ± 1.7 6.1 ± 1.8 0.01
% predicted 121 ± 22* 112 ± 21 110 ± 23 0.001
IC, L 1.8 ± 0.6 2.0 ± 0.6 2.0 ± 0.6 NS
% predicted 73 ± 21 77 ± 20 81 ± 19 NS
IC/TLC, % 28 ± 8* 32 ± 9 33 ± 8 <0.001
Incremental exercise test
Peak VO2 , L·min-1 0.85 ± 0.29* 1.02 ± 0.32* 1.12 ± 0.40 0.02
Peak VO2 , % predicted 61 ± 36* 75 ± 56* 87 ± 69 0.01
Peak work capacity, Watt 59 ± 22 69 ± 29 65 ± 29 NS
Peak work capacity, % predicted 57 ± 28 64 ± 41 64 ± 37 NS
Constant exercise test
CET time, s 367 ± 230 324 ± 201 338 ± 203 NS
6-minute walking test
6MWT, m 407 ± 75 391 ± 78 342 ± 79* 0.001
Work-walk, m·kg 23296 ± 5902* 29590 ± 8045* 32779 ± 11078* <0.001
Quality of life
SGRQ total score 45 ± 17 45 ± 16 45 ± 18 NS
SGRQ symptoms score 53 ± 23 51 ± 22 50 ± 24 NS
SGRQ activity score 65 ± 20 65 ± 20 65 ± 22 NS
SGRQ impact score 32 ± 18 32 ± 17 32 ± 19 NS
Pulmonary rehabilitation
Duration of rehabilitation (weeks) 8.5 ± 1.7 8.5 ± 1.7 8.4 ± 1.7 NS
Home based rehabilitation, n (%) 23 (26) 27 (28) 21 (27) NS
Values are mean ± SD. Definitions of abbreviations: FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; FRC: functional residual capacity; RV:
residual volume; TLC: total lung capacity; IC: inspiratory capacity; VO2 : oxygen consumption; CET: constant exercise test; 6MWT: 6-minutes walking test
distance; SGRQ: St-George’s respiratory questionnaire; NS: not significantly different. * = significantly different than the other two groups, p < 0.05. † =
significantly different than obese group, p < 0.05.
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results can be summarized as follow: i) obese and over-
weight patients had higher FEV1, lower static lung
volumes and higher peak incremental exercise capacity
at baseline, ii) despite this, their CET time was not
longer than that of patients with normal BMI, iii) obese
patients had a reduced walking capacity compared to
overweight and normal BMI patients, iv) BMI did not
seem to affect SGRQ scores in the present population,
finally v) overweight and obesity did not reduce the
magnitude of improvement in exercise capacity and
quality of life after pulmonary rehabilitation and BMI
had no effect on outcomes on univariate or multivariate
regression analyses taking account differences in base-
line pulmonary function.
It is interesting to observe that, in this cohort, the
proportion of overweight and obese patients was greater
than normal BMI patients, a likely reflection of the obe-
sity epidemic that afflicts industrialized countries
[32,33]. These results underscore that the study of the
impact of obesity and overweight in patients with
chronic respiratory disorders will be a topic of interest
in the coming years.
Obese and overweight patients had higher FEV1 and
FEV1/FVC ratio than their lean counterparts, an obser-
vation that was previously reported [3,4,34,35]. One pos-
sible explanation is that patients with weight excess tend
to be more dyspneic for a given FEV1[36] as illustrated
by the higher Borg dyspnea and leg fatigue scores found
in the obese patients during 6MWT. Therefore, obese
patients with COPD might attract medical attention at
an earlier stage of their disease. It is intriguing to con-
sider that obesity may influence the natural history of
COPD; in a subanalysis of the TORCH trial[37],
BMI >25 kg/m2 was associated with a slower decline in
FEV1. Another possibility for the differences in baseline
lung function relates to the influence of obesity on
ventilatory function. Decreased chest wall and lung
Figure 1 GOLD stage distribution across body mass index (BMI).
Figure 2 6-minute walking distance and endurance time to constant workrate exercise according to the 3 body mass index (BMI)
categories, at baseline and after pulmonary rehabilitation. Values are mean (SD). * = p < 0.01 baseline versus after rehabilitation within
each BMI group, † = p < 0.01 obese versus normal BMI, ‡ = p < 0.01 obese versus overweight.
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compliance in obesity[11] would tend to increase expira-
tory flows and decrease resting lung volumes.
At baseline, resting hyperinflation was reduced and
the IC/TLC ratio increased in the obese population.
This finding is consistent with those of Ora et al.[11].
One novel finding of our study is that overweight was
also associated with reduced lung volumes in compari-
son with patients with normal BMI.
We found that obesity had a significant impact on
walking capacity but not on the endurance time during
cycling exercise. This is likely the result of the increase
in energy expenditure associated with weight bearing
Figure 3 Dyspnea and leg fatigue Borg scores at the end of the 6-minute walking test (6MWT) and of constant workrate cycling
exercise (CET) according to the 3 body mass index (BMI) categories, at baseline and after pulmonary rehabilitation. Values are mean
(SD).). * = p < 0.01 obese versus normal BMI, † = p < 0.01, obese versus overweight, ‡ = p < 0.01 baseline versus after rehabilitation within each
BMI group.
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exercise[38] as shown by higher body weight-walking
distance product[25]. From a functional point of view,
walking better represents daily activities than cycling.
Taken together, these data suggest that obese COPD
patients might have more important functional impair-
ments. It would be interesting to study the impact of
weight reduction strategies on walking capacity in obese
patients with COPD.
As indicated by similar SGRQ total scores, there was
no difference in health status between groups, both at
baseline and post-rehabilitation, even though patients in
obese group had a more limited walking capacity. This
could be related to the fact that obese patients might
compensate by adapting their environment and dimin-
ishing the amount of activity they perform.
In a retrospective analysis, Ramachandran and collea-
gues[3] reported that the improvement in 6-min walking
distance and quality of life improved to a similar extent
after rehabiliation in obese patients with COPD when
compared with patients with a BMI < 30 mg/kg2. One
limitation of that study is that it did not include over-
weight patients. This appears to be relevant given that
overweight is even more common than obesity. Our
prospective study therefore adds to this information in
showing that dyspnea, quality of life and exercise toler-
ance improve as much in the obese and overweight
COPD patients as their normal BMI counterparts.
BODE scores improved significantly in our population
within each group to an extent that is consistent with
the literature[39].
We did not observe significant reductions in BMI after
pulmonary rehabilitation. Exercise in itself is usually not
Figure 4 Changes in St. George’s Respiratory Questionnaire (SGRQ) total score with pulmonary rehabilitation according to BMI
categories. The horizontal dashed line represents the minimally important clinical difference (MCID) for this variable (Δ of 4 units). Values are
mean (SD).
Table 2 Proportion of subjects reaching the MCID in each




6MWT, % 24* 18 15
CET, % 42 46 57
SGRQ, % 59 64 56
Dyspnea score at the end of 6MWT 46 37 46
Leg Fatigue score at the end of
6MWT
41 31 40
Dyspnea score at the end of CET 60 58 58
Leg fatigue score at the end of CET 56 51 60
Values are % of subjects reaching the MCID defined earlier on each group for
three different outcomes. Definitions of abbreviations: 6MWT: 6-minutes
walking test; CET: constant exercise test; SGRQ: St. George’s respiratory
questionnaire. * = p < 0.05 for normal BMI vs obese.
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sufficient to adequately manage obesity[40] and it
should be done in conjunction with nutritional counsel-
ing which was not offered here. In the future, it will be
important to learn how to intervene efficiently with
COPD patients in their goal of loosing excess fat.
This study provides some novel information. First, it
is, to our knowledge, the only study looking prospec-
tively at the effect of BMI on pulmonary rehabilitation
outcomes. We also report on improvements in terms of
MCID for 3 different outcomes, the 6 MWT, CET and
SGRQ. Although it is generally suspected that walking
capacity is compromised in obese COPD patients, this
study is the first to systematically investigate the impact
of obesity on specific exercise modalities. Finally, the
number of patients enrolled in our trial also provides
sufficient statistical power to make valid conclusions.
The impact of comorbid conditions on rehabilitation
outcomes is currently being investigated [41,42]. In gen-
eral, it is felt that comorbidities do not prevent pulmon-
ary rehabilitation from being effective although some
conditions such as metabolic diseases and osteoporosis
may reduce the chances of success [41,42]. The present
study extends these results by showing that obesity
reduces the likelihood of a patient achieving the MCID
of improvement in distance walked during the 6MWT
after rehabilitation. In contrast, the proportion of
patients reaching the MCID for cycle exercise and
SGRQ was not influenced by BMI. The proportion of
our patients reaching the MCID for the SGRQ is similar
to what has been reported [41]. Although we did not
record the amount of aerobic and resistance training
that was performed during rehabilitation, BMI was not a
factor in the choice of the training strategies and modal-
ities (home versus hospital-based) used in the three
groups. It is thus unlikely that intrinsic differences in
the design of the training programs were the main fac-
tors in explaining the lower proportion of obese patients
reaching the MCID for the 6MWT.
Although the improvement in 6MWT following pul-
monary rehabilitation was less than typically reported
[41,43], we felt that the CET data was reassuring about
the exercise enhancing effects of our rehabilitation pro-
grams. Measuring the cycling endurance time is a better
test of the functional effect of pulmonary rehabilitation
than the 6MWT[16]. The modest gain in the distance
covered during the 6MWT probably reflects our pro-
gram’s emphasis on the bicycling component of the
training intervention since the training modality is
known to impact on specific outcomes. For example,
patients training solely on stationary bicycle have less
improvement in walking capacity compared to patients
performing walking exercises[44].
Our study has potential limitations. First there were
only 3% of morbidly obese patients (BMI >40 kg/m2), it
would be important to see how such patients fare in the
context of pulmonary rehabilitation. Secondly, it is well
recognized that reduced fat free mass is associated with
muscle weakness[45], decreased exercise tolerance[46]
and poorer survival[47,48] in COPD. Reduced fat-free
mass may occur despite normal BMI[49]. Thirdly, the
CET and 6MWT dyspnea and leg fatigue Borg scores
were collected only at the end of exercise. Dyspnea and
leg fatigue scores obtained at isotime would have been
useful to assess the effects of pulmonary rehabilitation
on these variables in a more complete fashion. Finally,
the impairment in baseline FEV1 was greater in patients
normal BMI and the question may be raised as to
whether this difference in disease stage between groups
could explain our results. We do not believe that this is
the case for the following reasons: i) the main analysis
consisted in an analysis of covariance that took into
account any differences in FEV1 and lung volumes at
baseline; ii) since obese patients had milder airflow
obstruction and resting hyperinflation, their perfor-
mance during the 6MWT should have been better, not
worse; and iii) the magnitude of improvement following
pulmonary rehabilitation is independent from baseline
lung function[50].
Conclusion
Obesity and overweight are frequently associated with
COPD. As the prevalence of excess weight is increasing,
this association will be more and more frequent in clini-
cal practice. Obese patients with COPD, despite having
less severe airflow obstruction, resting hyperinflation
and better peak VO2 than normal BMI patients, had
more severe walking impairment. Pulmonary rehabilita-
tion was still beneficial in improving several clinical out-
comes despite the presence of excess weight. It would
be of great interest to study the impact of weight reduc-
tion strategies in conjunction to exercise training in this
specific patient population.
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